Pfizer and BioNTech: Covid-19 vaccine 80.3 percent effective in kids under 5

From: POLITICO Pulse - Monday May 23,2022 02:03 pm
Presented by Emergent: Delivered daily by 10 a.m., Pulse examines the latest news in health care politics and policy.
May 23, 2022 View in browser
 
POLITICO's Pulse newsletter logo

By Krista Mahr and Sarah Owermohle

Presented by Emergent

With help from Katherine Foley and Carmen Paun

Editor’s Note: POLITICO Pulse is a free version of POLITICO Pro Health Care's morning newsletter, which is delivered to our s each morning at 6 a.m. The POLITICO Pro platform combines the news you need with tools you can use to take action on the day’s biggest stories.  Act on the news with POLITICO Pro.

QUICK FIX

A Covid-19 vaccine for the youngest kids gets a little closer as Pfizer and BioNTech announce plans today to submit data to the FDA for their three pediatric doses.

Biden calls monkeypox something “everyone should be concerned about,” as the WHO confirms more than 90 cases in North America, Europe, the U.K., and Australia.

A judge blocks the Biden administration from lifting Title 42, keeping in place a public health policy the nation’s public health agency says is no longer necessary.

WELCOME TO MONDAY PULSE Singer Billie Eilish talks with David Letterman for his Netflix series about what it's like living with Tourette's syndrome. Send news and tips to kmahr@politico.com and sowermohle@politico.com.

 

A message from Emergent:

We go where travelers need vaccines against infectious disease — helping to protect global travelers as they explore new communities. Our vaccines and treatments have protected people worldwide from cholera, smallpox, anthrax and more. Learn how we’re preparing for what’s next at www.emergentbiosolutions.com

 
Driving the Day

FILE - Ilana Diener holds her son, Hudson, 3, during an appointment for a Moderna COVID-19 vaccine trial in Commack, N.Y. on Nov. 30, 2021. On Thursday, April 28, 2022, Moderna asked U.S. regulators to authorize low doses of its COVID-19 vaccine for children younger than 6, a long-awaited move toward potentially opening shots for millions of tots by summer. (AP Photo/Emma H. Tobin, File)

Pfizer and BioNTech is expected to submit new data to the FDA on a Covid-19 vaccine aimed at children ages 6 months to under 5 years. | AP

INCHING CLOSER TO THE UNDER-5 VACCINE —  This morning, Pfizer and BioNTech announced they plan to finish submitting data to the Food and Drug Administration on three doses of their Covid-19 vaccine for the 19 million children in the U.S. under 5 and still ineligible for any Covid-19 vaccine, Katherine reports.

The companies released top-line results showing that three pediatric doses of their Covid-19 vaccine generated a comparable immune response in children ages 6 months to under 5 years as two full doses did in young adults — the primary end goal the FDA set for pediatric vaccine manufacturers. Three doses of the vaccine also appeared to reduce cases of symptomatic disease by 80.3 percent within the age group.

The companies collected data on three doses of their vaccine in 1,678 children at least two months after they received their second vaccine dose. Omicron was the dominant variant of Covid-19 circulating at the time. No children in the trial had any serious side effects.

Background: Pfizer and BioNTech initially asked the FDA to authorize their two-shot Covid-19 regimen for kids 6 months to under 5 in February. The agency delayed the advisory committee meeting that would discuss the vaccine for this population, choosing to wait for more data on a third dose. Two doses of the vaccine generated immune responses in children 6 to 24 months old comparable to that in young adults but not in those between 2 and 5 years old.

What’s next: The FDA will schedule an advisory committee meeting to discuss the companies’ application when they complete their data submission.

 

DON'T MISS DIGITAL FUTURE DAILY - OUR TECHNOLOGY NEWSLETTER, RE-IMAGINED:  Technology is always evolving, and our new tech-obsessed newsletter is too! Digital Future Daily unlocks the most important stories determining the future of technology, from Washington to Silicon Valley and innovation power centers around the world. Readers get an in-depth look at how the next wave of tech will reshape civic and political life, including activism, fundraising, lobbying and legislating. Go inside the minds of the biggest tech players, policymakers and regulators to learn how their decisions affect our lives. Don't miss out, subscribe today.

 
 

This 2003 electron microscope image made available by the Centers for Disease Control and Prevention shows mature, oval-shaped monkeypox virions, left, and spherical immature virions, right, obtained from a sample of human skin associated with the 2003 prairie dog outbreak. Monkeypox, a disease that rarely appears outside Africa, has been identified by European and American health authorities in recent days. (Cynthia S. Goldsmith, Russell Regner/CDC via AP)

The monkeypox virus, shown here under a microscope, rarely appears outside Africa, but it's turned up in other countries, including the U.S., recently. | AP

WHY ARE WE ALL TALKING ABOUT MONKEYPOX? — Before leaving South Korea on Sunday, President Joe Biden referred to monkeypox, the contagious virus that’s spreading quickly in some countries, as endemic to West Africa and “something that everyone should be concerned about.”

The same day, White House Covid-19 response coordinator Ashish Jha tried to draw a clear line between monkeypox and Covid-19 on the Sunday shows, reports POLITICO’s David Cohen . “We have vaccines against it; we have treatments against it,” he said. “And it is spread very differently than SARS-CoV-2.”

Monkeypox by the numbers: On Saturday, the World Health Organization reported 92 lab-confirmed cases and 28 suspected cases in 12 countries in North America, Australia, Europe and the U.K. So far, the CDC has only confirmed one case in the U.S. in the Boston area, health and senior administration officials said on Friday, though other suspected cases have been reported.

The officials said the cases have been spreading primarily — but not exclusively — among men who have intimate contact, including but not limited to sexual activity, with other men.

Why public health officials are watching this so closely: The reported cases, including the U.S. case, aren’t linked to any of the 12 countries in West and Central Africa where monkeypox is endemic.

“This case is highly unusual, and we do have a degree of scientific concern about it,” a senior U.S. health official told reporters Friday. “So far, it doesn't have any direct link to any of the countries in West and Central Africa where monkeypox is commonly found.

The official cautioned that while additional cases may be reported in the coming days, the virus still poses a “low risk” to Americans at this time.

TITLE 42, IN THE NAME OF PUBLIC HEALTH NO MORE — On Friday, a federal judge blocked the Biden administration from lifting the public health order Title 42 today, continuing the expulsion of migrants from the U.S. on public health grounds the CDC says is no longer necessary.

More than 20 states had sued the administration over the way it ended the policy, first enacted in March 2020 during the early days of the pandemic, and the impact a potential surge in migrants would have on states. The administration said the Department of Justice will appeal the decision but would continue to enforce the order during the appeal process.

This will evidently be welcome news to the majority of Americans who oppose the Biden administration’s decision to end Title 42, according to a new POLITICO-Harvard survey, underscoring how a law designed to stop the spread of disease is now widely seen as the best way to control immigration.

The survey found that 55 percent of American adults oppose ending the use of the order, known as Title 42, to prevent migrants from entering the U.S., compared to 45 percent who think the order should end.

Among those who said they think there should be less immigration into the U.S., opposition to ending the order rose to 77 percent, while 72 percent of people who support more immigration think the order should end.

 

A message from Emergent:

Advertisement Image

 
Around the Agencies

BECERRA INVOKES DPA TO EASE BABY FORMULA SHORTAGE ... Health and Human Services Secretary Xavier Becerra invoked the Defense Production Act on Sunday to help manufacturers get the materials they need to ramp up production of infant formula during the national shortage.

Two manufacturers — Abbott Nutrition and Reckitt — can now “add legally binding language to their orders with suppliers that will give them priority over other customers,” the administration said in a statement.

The DPA order will authorize Abbott, which requested federal government assistance, to obtain “priority fulfillment” over the next three months for goods needed to manufacture formula like corn syrup and sugar and Reckitt to access products like filters that are held up in the supply chain.

Earlier in the day, 35 tons of Swiss baby formula arrived via cargo plane in Indianapolis, enough to feed 9,000 babies and 18,000 toddlers for a week.

... AND RESPONDS TO WHO CONSPIRACY THEORY Claims that revising international health rules would diminish U.S. sovereignty “are categorically false and dangerous,” Becerra wrote on social media Friday, Carmen reports.

The message was in response to a conspiracy theory that’s been picked up online claiming the U.S. is planning to hand over sovereignty to the World Health Organization at a meeting this week in Geneva. At least one Biden-Harris administration official received thousands of emails about it.

The conspiracy stems from a U.S proposal to revise the International Health Regulations, which govern how the world responds to a disease outbreak. Conspiracy theorists seized on a proposal to delete current wording noting that a country should agree that an outbreak poses international concern before convening a committee to declare so. They claim this would give the WHO unchecked control over the U.S. and other countries.

Fox News commentator Tucker Carlson mentioned it during his show Thursday. Media personalities in the U.K. and politicians in Australia have amplified the theory.

For the record, the WHO is not plotting a global takeover. The regulations, which in theory should be respected by all 194 WHO member countries, have no way to punish a government for not following them.

 

STEP INSIDE THE WEST WING: What's really happening in West Wing offices? Find out who's up, who's down, and who really has the president’s ear in our West Wing Playbook newsletter, the insider's guide to the Biden White House and Cabinet. For buzzy nuggets and details that you won't find anywhere else, subscribe today.

 
 
In the States

STATE DEMS WANT MORE EXECUTIVE ACTION ON ABORTION — Democrats in states want to see the White House swing into action to secure access to abortion, POLITICO’s Megan Messerly and Alice Miranda Ollstein report.

Since the draft opinion overturning Roe v. Wade became public, national Democrats have largely highlighted what they can’t do in the Senate and focused on fueling midterm-election turnout instead of taking executive action that could increase access to abortion pills or help protect people’s medical information.

The lack of federal action is forcing members of Congress and national reproductive-rights groups to concede that state and local action is their best and possibly only option — even if it means tens of millions of people could be left without access to abortion.

“At this juncture, the state is going to be the lead,” Michigan Democratic Gov. Gretchen Whitmer told POLITICO. “We’re not waiting for someone else to solve this. We’re moving forward.”

What We're Reading

A new report from Stat News’ Casey Ross details how HIPAA allows companies to traffic in Americans’ health data without their knowledge or consent.

Insider’s Madison Hall and Walt Hickey dig into how tobacco giant Reynolds American is spending millions of dollars in state-level politics.

A patient who needed back surgery after a car accident was told the procedure would cost $1,337. The hospital charged her $229,112.13, The New York Times reports.

 

A message from Emergent:

We help defend against things we hope will never happen – so we are prepared, in case they ever do.

For more than two decades, Emergent has developed, manufactured and delivered protections against critical health threats. Our vaccines and treatments have fought cholera, smallpox, anthrax – protecting doctors, America’s service members and more.

We do what we do because we believe in a better, more secure world. One where we’re ready for the unknown and one where peace of mind prevails. Learn more about protecting public health at www.emergentbiosolutions.com

 
 

Follow us on Twitter

Tucker Doherty @tucker_doherty

Dan Goldberg @dancgoldberg

Erin Banco @ErinBanco

Katherine Ellen Foley @katherineefoley

Lauren Gardner @Gardner_LM

Ben Leonard @_BenLeonard_

Rachael Levy @rachael_levy

David Lim @davidalim

Krista Mahr @kristamahr

Megan Messerly @meganmesserly

Alice Miranda Ollstein @aliceollstein

Sarah Owermohle @owermohle

Carmen Paun @carmenpaun

Megan R. Wilson @misswilson

 

Follow us

Follow us on Facebook Follow us on Twitter Follow us on Instagram Listen on Apple Podcast
 

To change your alert settings, please log in at https://www.politico.com/_login?base=https%3A%2F%2Fwww.politico.com/settings

This email was sent to by: POLITICO, LLC 1000 Wilson Blvd. Arlington, VA, 22209, USA

Please click here and follow the steps to .

More emails from POLITICO Pulse